Страна: Канада
Език: английски
Източник: Health Canada
IRBESARTAN
MYLAN PHARMACEUTICALS ULC
C09CA04
IRBESARTAN
75MG
TABLET
IRBESARTAN 75MG
ORAL
90
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0131700001; AHFS:
CANCELLED POST MARKET
2018-08-03
PRODUCT MONOGRAPH PR MYLAN-IRBESARTAN Irbesartan Tablets USP 75 mg, 150 mg and 300 mg Angiotensin II AT 1 Receptor Blocker Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Submission Control No. 189187 Date of Revision: November 16, 2015 2 PRODUCT MONOGRAPH PR MYLAN-IRBESARTAN Irbesartan Tablets USP 75 mg, 150 mg and 300 mg THERAPEUTIC CLASSIFICATION Angiotensin II AT 1 Receptor Blocker ACTION AND CLINICAL PHARMACOLOGY MECHANISM OF ACTION MYLAN-IRBESARTAN (irbesartan) antagonizes angiotensin II by blocking AT 1 receptors. Angiotensin II is the primary vasoactive hormone in the renin-angiotensin system. Its effects include vasoconstriction and the stimulation of aldosterone secretion by the adrenal cortex. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking in a non competitive manner the binding of angiotensin II to the AT 1 receptor found in many tissues. Irbesartan has no agonist activity at the AT 1 receptor. AT 2 receptors have been found in many tissues, but to date they have not been associated with cardiovascular homeostasis. Irbesartan has essentially no affinity for the AT 2 receptors. Irbesartan does not inhibit angiotensin converting enzyme, also known as kinase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it affect renin or other hormone receptors or ion channels involved in cardiovascular regulation of blood pressure and sodium homeostasis. PHARMACOKINETICS _ABSORPTION:_ Irbesartan is an orally active agent. The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% - 80%. Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range with an average terminal elimination half-life of 11-15 hours. Following oral administration, peak plasma concentrations are attained at 1.5-2 hours after dosing. Steady-state concentrations are achieved within 3 days. _DISTRIBUTION:_ Irbesartan is approximately 96% protein-bound in the p Прочетете целия документ